Type 2 Diabetes

NovoMix 30 helps people with type 2 diabetes achieve recommended blood glucose targets

Published in Pharma Law Weekly, January 9th, 2007

NovoMix 30 insulin significantly improved long-term control of blood glucose in people with type 2 diabetes who were previously in poor glycaemic control while taking metformin and pioglitazone alone, according to new data presented at the International Diabetes Federation congress in Cape Town, South Africa.

"Patients are too often treated only with OADs long after insulin therapy should have been initiated, resulting in poor glycaemic control and an increased risk of serious, long-term complications," said lead investigator Phillip Raskin, M.D., professor, University of Texas, Southwestern Medical Center. "In fact, our study showed that no patient with an HbA1c level...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Pharma Law Weekly

Source: Pharma Law Weekly (2007-01-09)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry